Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evogene Ltd Ord (EVGN)

Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,473
  • Shares Outstanding, K 5,365
  • Annual Sales, $ 8,510 K
  • Annual Income, $ -16,490 K
  • EBIT $ -14 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.28
  • Price/Sales 0.94
  • Price/Cash Flow N/A
  • Price/Book 0.31

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9300 +9.68%
on 12/30/25
1.2100 -15.70%
on 01/06/26
-0.0100 (-0.97%)
since 12/22/25
3-Month
0.9300 +9.68%
on 12/30/25
1.3300 -23.31%
on 10/29/25
-0.2500 (-19.69%)
since 10/22/25
52-Week
0.9300 +9.68%
on 12/30/25
2.4200 -57.85%
on 06/10/25
-0.7800 (-43.33%)
since 01/22/25

Most Recent Stories

More News
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and patient-derived predictive platform...

EVGN : 1.0300 (+0.98%)
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

REHOVOT, Israel , Dec. 30, 2025 /PRNewswire/ --  Evogene Ltd . (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules...

EVGN : 1.0300 (+0.98%)
Evogene: Q3 Earnings Snapshot

Evogene: Q3 Earnings Snapshot

EVGN : 1.0300 (+0.98%)
Evogene Reports Third Quarter 2025 Financial Results

Conference call and webcast: today, November 20, 2025, 9:00 AM ET

EVGN : 1.0300 (+0.98%)
Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Collaboration focuses on integrating high-yield castor varieties with advanced mechanized solutions, including harvesting and threshing technologies

EVGN : 1.0300 (+0.98%)
Evogene Schedules Third Quarter 2025 Financial Results Release

Zoom conference call scheduled for November 20, 2025, 9:00 AM ET

EVGN : 1.0300 (+0.98%)
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

REHOVOT, Israel , Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ : EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer...

EVGN : 1.0300 (+0.98%)
Evogene: Q2 Earnings Snapshot

Evogene: Q2 Earnings Snapshot

EVGN : 1.0300 (+0.98%)
Evogene Reports Second Quarter 2025 Financial Results

Conference call and webcast: today, August 19, 2025 , 9:00 am ET

EVGN : 1.0300 (+0.98%)
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia   and Gout.

EVGN : 1.0300 (+0.98%)

Business Summary

Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene...

See More

Key Turning Points

3rd Resistance Point 1.0667
2nd Resistance Point 1.0533
1st Resistance Point 1.0367
Last Price 1.0300
1st Support Level 1.0067
2nd Support Level 0.9933
3rd Support Level 0.9767

See More

52-Week High 2.4200
Fibonacci 61.8% 1.8508
Fibonacci 50% 1.6750
Fibonacci 38.2% 1.4992
Last Price 1.0300
52-Week Low 0.9300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar